rituximab
Selected indexed studies
- A tale of two antibodies: obinutuzumab versus rituximab. (Br J Haematol, 2018) [PMID:29741753]
- Rituximab in Subepidermal Blistering Diseases. (Dermatology, 2023) [PMID:36302346]
- Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. (Front Immunol, 2019) [PMID:31555262]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- A tale of two antibodies: obinutuzumab versus rituximab. (2018) pubmed
- Rituximab in Subepidermal Blistering Diseases. (2023) pubmed
- Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. (2019) pubmed
- Rituximab for myasthenia gravis. (2025) pubmed
- Rituximab resistance in ITP and beyond. (2023) pubmed
- Rituximab for people with multiple sclerosis. (2025) pubmed
- Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy. (2021) pubmed
- Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. (2020) pubmed
- Rituximab for people with multiple sclerosis. (2021) pubmed
- Rituximab biosimilars for lymphoma in Europe. (2019) pubmed